Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies
Ended the quarter with $29.0 million in cash, cash equivalents and short-term investments plus $1.8 million in collaboration receivables related to the Company's Théa Open Innovation (TOI or Théa) partnership.Encinitas, California--(Newsfile Corp. - November 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key third quarter and recent corporate highlights include:
加利福尼亞州恩西尼塔斯--（Newsfile Corp.，2024年11月8日）——Kiora Pharmicals, Inc.（納斯達克股票代碼：KPRX）（「Kiora」 或 「公司」）今天公佈了2024年第三季度財務業績，並提供了其治療視網膜疾病療法的最新情況。第三季度和最近的公司亮點包括：
Investigational new drug application approval to initiate ABACUS-2, the Phase 2 study of KIO-301, a novel molecular photoswitch, for the treatment of retinitis pigmentosa.
Finalized the design of the Phase 2 KLARITY trial of KIO-104, a small molecule targeting the treatment of multiple retinal inflammatory diseases, with submission for trial approval on track for Q4 2024.
Ended the quarter with $29.0 million in cash, cash equivalents and short-term investments plus $1.8 million in collaboration receivables related to the Company's Théa Open Innovation (TOI or Théa) partnership.
Expected runway into 2027, excluding any potential partnership milestones.
啓動用於治療色素性視網膜炎的新型分子光開關 KIO-301 的二期研究 ABACUS-2 的在研新藥申請獲得批准。
完成了靶向治療多種視網膜炎性疾病的小分子 KIO-104 的 KLARITY 二期試驗的設計，有望在 2024 年第四季度提交試驗批准。
本季度末有2900萬澳元的現金、現金等價物和短期投資，以及與公司The'a開放創新（TOI或Thea）合作伙伴關係相關的180萬美元合作應收賬款。
預計將持續到2027年，不包括任何潛在的合作里程碑。
"Kiora remains in a strong position with two compelling and innovative drug candidates entering Phase 2 clinical trials and a strong balance sheet to fund development and operations beyond anticipated readouts for both studies," said Brian M. Strem, Ph.D., President & Chief Executive Officer of Kiora. "During the third quarter, we worked diligently to prepare for these trials, which will increase their likelihood of success.
Kiora總裁兼首席執行官Brian m. Strem博士表示：「Kiora仍然處於強勢地位，有兩種引人注目的創新候選藥物進入2期臨床試驗，資產負債表強勁，爲兩項研究的開發和運營提供超出預期水平的資金。」“在第三季度，我們努力爲這些試驗做準備，這將增加他們成功的可能性。
"Regarding KIO-301, we recently received approval to initiate ABACUS-2, a 36-patient, multi-center, double-masked, randomized, controlled, multi-dose study in patients with ultra-low vision or no light perception due to retinitis pigmentosa. Based on KIO-301's differentiated mechanism of action as a small molecule, we will enroll patients with any of the known 150-plus underlying gene mutations associated with retinitis pigmentosa. Dosing of the first patient with KIO-301 will begin next year following the completion of the ongoing validation work around functional vision endpoints.
“關於 KIO-301，我們最近獲准啓動 ABACUS-2，這是一項針對因色素性視網膜炎導致的超低視力或無光感知患者的36名患者、多中心雙面罩、隨機、對照、多劑量研究。根據 KIO-301 作爲小分子的差異化作用機制，我們將招收任何與色素性視網膜炎相關的已知 150 多個潛在基因突變的患者。在圍繞功能視覺終點的持續驗證工作完成後，將於明年開始對首位 KIO-301 患者進行給藥。
"Following multiple interactions with the FDA and European regulators, retinal specialists, and patient advocacy groups, it's clear that demonstrating improvement in functional vision is essential for marketing authorization as well as reimbursement. Thus, throughout the third quarter and continuing into the fourth, we've invested time to validate functional vision endpoints, increasing the probability of success of ABACUS-2 and a potential Phase 3 study in the US and Europe. This validation work is being performed in collaboration with our partner Théa, with additional support from the Choroideremia Research Foundation.
“在與美國食品藥品管理局和歐洲監管機構、視網膜專家和患者權益團體進行了多次互動之後，很明顯，證明功能性視力的改善對於上市許可和報銷至關重要。因此，在整個第三季度一直持續到第四季度，我們投入了時間來驗證功能視覺終點，提高了 ABACUS-2 以及可能在美國和歐洲進行的 3 期研究的成功概率。這項驗證工作是與我們的合作伙伴Theía合作進行的，並得到了Choroideremia研究基金會的額外支持。
"Our other active program is KIO-104, a potent, locally delivered small molecule that we are developing to treat inflammatory retinal diseases. The goal is to offer patients and providers an alternative to chronic steroid use or systemic anti-inflammatory drugs, both of which often lead to complications. KIO-104 acts by suppressing specific types of T cells and their resulting biomolecules (cytokines) that underlie damaging inflammation. Following a previously successful first-in-man study, we now plan to initiate KLARITY in the first half of next year. This study will be a Phase 2 clinical trial to explore multiple doses of KIO-104 in patients with inflammatory retinal diseases, including posterior non-infectious uveitis and diabetic macular edema. Findings in the study will inform a dose expansion trial in one or more specific indications."
「我們的另一個活躍項目是 KIO-104，這是一種有效的局部遞送小分子，我們正在開發用於治療炎性視網膜疾病。目標是爲患者和醫療服務提供者提供長期使用類固醇或全身性消炎藥的替代方案，這兩種藥物通常都會導致併發症。KIO-104 通過抑制特定類型的 T 細胞及其產生的構成破壞性炎症基礎的生物分子（細胞因子）起作用。繼此前成功的首次人體研究之後，我們現在計劃在明年上半年啓動KLARITY。這項研究將是一項 2 期臨床試驗，旨在探討炎性視網膜疾病（包括後部非感染性葡萄膜炎和糖尿病性黃斑水腫）患者服用多劑量的 KIO-104。該研究的結果將爲一項或多種特定適應症的劑量擴展試驗提供信息。」
Kiora's Chief Financial Officer, Melissa Tosca, added, "We continue to efficiently manage our cash while creating value by investing in our pipeline. Our Théa partnership enables our overall pipeline progress through their reimbursement of our KIO-301 R&D activities, allowing us to invest further in KIO-104. Going forward, we anticipate R&D expenses will increase as we begin patient enrollment in the KLARITY trial. However, we maintain a cash runway into 2027, before any potential partnership milestones, and beyond the expected data readouts from ABACUS-2 and KLARITY."
Kiora的首席財務官梅利莎·托斯卡補充說：「我們將繼續有效地管理現金，同時通過投資管道來創造價值。我們與 Thea 的合作伙伴關係通過補償我們的 KIO-301 研發活動來推動我們的總體研發進展，從而使我們能夠進一步投資於 KIO-104。展望未來，隨着我們開始註冊KLARITY試驗的患者，我們預計研發費用將增加。但是，我們將現金流維持到2027年，在任何潛在的合作里程碑之前，以及在 ABACUS-2 和 KLARITY 的預期數據讀出之後。」
Third Quarter Financial Highlights
第三季度財務摘要
Kiora ended the third quarter of 2024 with $29.0 million in cash and cash equivalents and short-term investments. In addition, the Company recorded $1.8 million in collaboration receivables from TOI for reimbursed R&D expenses and $0.4 million R&D incentive tax credits. The increase in cash position from the prior quarter was due primarily to the receipt of $1.5 million in R&D incentive tax credits.
Kiora在2024年第三季度結束時獲得了2900萬美元的現金和現金等價物以及短期投資。此外，該公司記錄了來自TOI的180萬美元合作應收賬款，用於報銷的研發費用和40萬美元的研發激勵稅收抵免。與上一季度相比，現金狀況的增加主要是由於獲得了150萬美元的研發激勵稅收抵免。
Research and development expenses for the third quarter of 2024 were $2.2 million, before recognizing $0.9 million in reimbursement from Théa. This resulted in net research and development expenses for the third quarter of 2024 of $1.3 million compared to $1.1 million in R&D expenses in the third quarter of 2023, during which time there were no partnership-related reimbursement credits. The year-over-year increase was primarily due to research activities related to KIO-301 and KIO-104.
2024年第三季度的研發費用爲220萬美元，之後確認了Theía的90萬美元報銷。這使2024年第三季度的研發支出淨額爲130萬美元，而2023年第三季度的研發費用爲110萬美元，在此期間沒有與合作伙伴關係相關的報銷抵免。同比增長主要歸因於與 KIO-301 和 KIO-104 相關的研究活動。
General and administrative expenses were $1.4 million for the third quarter of 2024, no change from the $1.4 million spent in the third quarter of 2023.
2024年第三季度的一般和管理費用爲140萬美元，與2023年第三季度的140萬美元相比沒有變化。
Net loss was $3.4 million for the third quarter of 2024 compared to a net loss of $5.8 million for the third quarter of 2023. The decrease in net loss is primarily attributed to a non-cash component, the change in fair value of contingent consideration, of -$1.1 million in the third quarter of 2024 related to the strategic decision to focus on KIO-301 and KIO-104 and halt any continuing development and licensing activities for KIO-201.
2024年第三季度的淨虧損爲340萬美元，而2023年第三季度的淨虧損爲580萬美元。淨虧損的減少主要歸因於2024年第三季度非現金部分，即或有對價公允價值的變化，爲-110萬美元，這與專注於 KIO-301 和 KIO-104 並停止 KIO-201 任何持續開發和許可活動的戰略決策有關。
About Kiora Pharmaceuticals
關於 Kiora 製藥
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase. In addition to news releases and SEC filings, we expect to post information on our website, , and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.
Kiora Pharmaceuticals是一家臨床階段的生物技術公司，正在開發和商業化治療孤兒視網膜疾病的產品。KIO-301 正在開發用於治療色素性視網膜炎、脈絡膜血癥和斯塔加特病。它是一種分子光電開關，有可能恢復遺傳性和/或年齡相關性視網膜變性患者的視力。KIO-104 正在開發用於治療視網膜炎症。它是二氫乳清酸脫氫酶的下一代非甾體免疫調節小分子抑制劑。除了新聞稿和美國證券交易委員會文件外，我們預計還將在我們的網站和社交媒體帳戶上發佈可能與投資者相關的信息。我們鼓勵投資者在推特和領英上關注我們，訪問我們的網站和/或訂閱電子郵件提醒。
Forward-Looking Statements
前瞻性陳述
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, Kiora's ability to execute on development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-104 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all, the sufficiency of existing cash on hand to fund operations for specific periods, the projected cash runway, the ability to timely complete planned initiatives for 2024, including phase 2 clinical development of KIO-301 and KIO-104, the potential for KIO-301 to be the first treatment options for patients with inherited degenerative diseases like RP, Kiora's plans to further fund development of KIO-104, the potential for KIO-104 to reduce inflammation, the timing of topline results from clinical trials of KIO-104, the potential for KIO-104 to apply to other retinal inflammatory diseases, the anticipated readout dates for Kiora's clinical trials and their likelihood of success, and expected trends for research and development and general and administrative spending in 2024. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading "Risk Factors" contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 25, 2024 or described in Kiora's other public filings including on Form 10-Q filed with the SEC on November 8, 2024. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.
本新聞稿中的一些聲明是 「前瞻性的」，是根據1995年《私人證券訴訟改革法》的安全港條款作出的。這些 「前瞻性」 陳述包括與Kiora執行開發和商業化工作以及與Kiora開發階段產品（包括 KIO-104 和 KIO-301）相關的其他監管或營銷批准工作的能力以及其成功的陳述，此類批准或成功可能無法及時獲得或實現，或根本無法獲得或根本無法獲得或根本無法獲得或根本沒有足夠的手頭現金爲特定時期的運營提供資金，預計的現金跑道，及時完成計劃的能力2024 年的舉措，包括 KIO-301 和 KIO-104 的二期臨床開發、KIO-301 可能成爲遺傳性退行性疾病（如 RP）患者的首選治療方案、Kiora 進一步資助開發 KIO-104 的計劃、KIO-104 減少炎症的可能性、KIO-104 臨床試驗結果公佈的時機、KIO-104 應用於其他視網膜炎性疾病的可能性、Kiora 臨床試驗的預期讀出日期及其可能性成功與預期的研究趨勢以及2024年的發展、一般和行政支出。這些聲明涉及風險和不確定性，可能導致結果與本新聞稿中列出的聲明、及時進行臨床試驗的能力、市場和其他條件以及某些風險因素存在重大差異，這些風險因素載於Kiora於2024年3月25日向美國證券交易委員會提交的10-k表年度報告中所述，或Kiora的其他公開文件，包括2024年11月8日向美國證券交易委員會提交的10-Q表中所述。Kiora的業績還可能受到Kiora目前尚未意識到的因素的影響。本新聞稿中的前瞻性陳述僅代表截至本新聞稿發佈之日。除非法律要求，否則Kiora明確表示不承擔任何義務或承諾公開發布此類聲明的任何更新或修訂，以反映其對該聲明的期望的任何變化或任何此類聲明所依據的事件、條件或情況的任何變化。
###
###
Contact:
investors@kiorapharma.com
聯繫人：
investors@kiorapharma.com
CONDENSED CONSOLIDATED BALANCE SHEETS
簡明的合併資產負債表
| September 30, 2024 (unaudited) | December 31, 2023 | |||||
| ASSETS | ||||||
| Current Assets: | ||||||
| Cash and Cash Equivalents | $ | 5,637,019 | $ | 2,454,684 | ||
| Short-Term Investments | 23,398,016 | - | ||||
| Prepaid Expenses and Other Current Assets | 470,424 | 233,382 | ||||
| Collaboration Receivables | 1,783,472 | - | ||||
| Tax and Other Receivables | 363,706 | 2,049,965 | ||||
| Total Current Assets | 31,652,637 | 4,738,031 | ||||
| Non-Current Assets: | ||||||
| Property and Equipment, Net | 62,609 | 8,065 | ||||
| Restricted Cash | 4,520 | 4,267 | ||||
| Intangible Assets and In-Process R&D, Net | 6,687,100 | 8,813,850 | ||||
| Operating Lease Assets with Right-of-Use | 72,637 | 106,890 | ||||
| Other Assets | 29,851 | 40,767 | ||||
| Total Assets | $ | 38,509,354 | $ | 13,711,870 | ||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
| Current Liabilities: | ||||||
| Accounts Payable | $ | 660,415 | $ | 206,260 | ||
| Accrued Expenses | 1,714,211 | 1,380,666 | ||||
| Accrued Collaboration Credit | 1,119,591 | - | ||||
| Operating Lease Liabilities | 33,447 | 47,069 | ||||
| Total Current Liabilities | 3,527,664 | 1,633,995 | ||||
| Non-Current Liabilities: | ||||||
| Contingent Consideration | 4,133,008 | 5,128,959 | ||||
| Deferred Tax Liability | 779,440 | 779,440 | ||||
| Operating Lease Liabilities | 39,190 | 59,822 | ||||
| Total Non-Current Liabilities | 4,951,638 | 5,968,221 | ||||
| Total Liabilities | 8,479,302 | 7,602,216 | ||||
| Commitments and Contingencies (Note 8) | ||||||
| Stockholders' Equity: | ||||||
| Preferred Stock, $0.01 Par Value: 10,000,000 shares authorized; 3,750 designated Series A, 0 shares issued and outstanding; 10,000 designated Series B, 0 shares issued and outstanding; 10,000 shares designated Series C, 0 shares issued and outstanding; 20,000 shares designated Series D, 7 shares issued and outstanding; 1,280 shares designated Series E, 0 shares issued and outstanding; 3,908 shares designated Series F, 420 issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 4 | 4 | ||||
| Common Stock, $0.01 Par Value: 150,000,000 and 50,000,000 shares authorized; 3,000,788 and 856,182 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 267,679 | 77,078 | ||||
| Additional Paid-In Capital | 168,996,195 | 153,192,228 | ||||
| Accumulated Deficit | (139,158,620) | (146,976,855) | ||||
| Accumulated Other Comprehensive Loss | (75,206) | (182,801) | ||||
| Total Stockholders' Equity | 30,030,052 | 6,109,654 | ||||
| Total Liabilities and Stockholders' Equity | $ | 38,509,354 | $ | 13,711,870 |
| 2024 年 9 月 30 日（未經審計） | 2023 年 12 月 31 日 | |||||
| 資產 | ||||||
| 流動資產： | ||||||
| 現金和現金等價物 | $ | 5,637,019 | $ | 2,454,684 | ||
| 短期投資 | 23,398,016 | - | ||||
| 預付費用和其他流動資產 | 470,424 | 233,382 | ||||
| 合作應收賬款 | 1,783,472 | - | ||||
| 稅收和其他應收賬款 | 363,706 | 2,049,965 | ||||
| 流動資產總額 | 31,652,637 | 4,738,031 | ||||
| 非流動資產： | ||||||
| 財產和設備，淨額 | 62,609 | 8,065 | ||||
| 限制性現金 | 4,520 | 4,267 | ||||
| 無形資產和在建研發，淨額 | 6,687,100 | 8,813,850 | ||||
| 具有使用權的經營租賃資產 | 72,637 | 106,890 | ||||
| 其他資產 | 29,851 | 40,767 | ||||
| 總資產 | $ | 38,509,354 | $ | 13,711,870 | ||
| 負債和股東權益 | ||||||
| 流動負債： | ||||||
| 應付賬款 | $ | 660,415 | $ | 206,260 | ||
| 應計費用 | 1,714,211 | 1,380,666 | ||||
| 應計合作積分 | 1,119,591 | - | ||||
| 經營租賃負債 | 33,447 | 47,069 | ||||
| 流動負債總額 | 3,527,664 | 1,633,995 | ||||
| 非流動負債： | ||||||
| 或有對價 | 4,133,008 | 5,128,959 | ||||
| 遞延所得稅負債 | 779,440 | 779,440 | ||||
| 經營租賃負債 | 39,190 | 59,822 | ||||
| 非流動負債總額 | 4,951,638 | 5,968,221 | ||||
| 負債總額 | 8,479,302 | 7,602,216 | ||||
| 承付款項和或有開支（注8） | ||||||
| 股東權益： | ||||||
| 優先股，面值0.01美元：授權1,000,000股；指定A系列3,750股，已發行和流通股票；1萬股指定b系列，0股已發行和流通；1萬股指定D系列，7股已發行和流通；1,280股指定E系列，0股已發行和流通；3,908股指定F系列，420股已發行和流通，2024年9月30日和12月31日分別是 2023 年 | 4 | 4 | ||||
| 普通股，面值0.01美元：已授權1.5億股和5000萬股；截至2024年9月30日和2023年12月31日分別已發行和流通的3,000,788股和856,182股股票 | 267,679 | 77,078 | ||||
| 額外的實收資本 | 168,996,195 | 153,192,228 | ||||
| 累計赤字 | (139,158,620) | (146,976,855) | ||||
| 累計其他綜合虧損 | (75,206) | (182,801) | ||||
| 股東權益總額 | 30,030,052 | 6,109,654 | ||||
| 負債總額和股東權益 | $ | 38,509,354 | $ | 13,711,870 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE INCOME (LOSS)
(unaudited)
簡明的合併運營報表以及
綜合收益（虧損）
（未經審計）
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Revenue: | ||||||||||||
| Collaboration Revenue | $ | - | $ | - | $ | 16,000,000 | $ | - | ||||
| Grant Revenue | - | - | 20,000 | - | ||||||||
| Total Revenue | - | - | 16,020,000 | - | ||||||||
| Operating Expenses: | ||||||||||||
| General and Administrative | 1,380,997 | 1,415,844 | 4,215,411 | 3,782,596 | ||||||||
| Research and Development | 1,317,231 | 1,085,010 | 3,717,570 | 2,915,392 | ||||||||
| In-Process R&D Impairment | 2,008,000 | 1,904,314 | 2,008,000 | 1,904,314 | ||||||||
| Change in Fair Value of Contingent Consideration | (1,103,991) | 1,513,400 | (995,951) | 1,865,945 | ||||||||
| Total Operating Expenses | 3,602,237 | 5,918,568 | 8,945,030 | 10,468,247 | ||||||||
| Operating Income (Loss) | (3,602,237) | (5,918,568) | 7,074,970 | (10,468,247) | ||||||||
| Other Income (Expense), Net: | ||||||||||||
| Interest Income, Net | 248,840 | 49,912 | 813,989 | 128,464 | ||||||||
| Other Income (Expense), Net | (59,929) | 105,715 | (70,724) | 94,493 | ||||||||
| Total Other Income, Net | 188,911 | 155,627 | 743,265 | 222,957 | ||||||||
| Net Income (Loss) | $ | (3,413,326) | $ | (5,762,941) | $ | 7,818,235 | $ | (10,245,290) | ||||
| Deemed Dividends from Warrant Reset Provision | - | (530,985) | - | (530,985) | ||||||||
| Net Loss Attributable to Common Shareholders | $ | (3,413,326) | $ | (6,293,926) | $ | 7,818,235 | $ | (10,776,275) | ||||
| Net Income (Loss) per Common Share - Basic | $ | (0.81) | $ | (7.30) | $ | 2.08 | $ | (23.35) | ||||
| Weighted Average Shares Outstanding - Basic | 4,214,950 | 789,656 | 3,757,467 | 438,687 | ||||||||
| Net Income (Loss) per Common Share - Diluted | $ | (0.81) | $ | (7.30) | $ | 1.91 | $ | (23.35) | ||||
| Weighted Average Shares Outstanding - Diluted | 4,214,950 | 789,656 | 4,092,880 | 438,687 | ||||||||
| Other Comprehensive Income (Loss): | ||||||||||||
| Net Income (Loss) | $ | (3,413,326) | $ | (5,762,941) | $ | 7,818,235 | $ | (10,245,290) | ||||
| Unrealized Gain on Marketable Securities | 76,435 | - | 73,607 | - | ||||||||
| Foreign Currency Translation Adjustments | 94,094 | (40,310) | 33,988 | (83,430) | ||||||||
| Comprehensive Income (Loss) | $ | (3,242,797) | $ | (5,803,251) | $ | 7,925,830 | $ | (10,328,720) | ||||
| 截至9月30日的三個月 | 截至9月30日的九個月 | |||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| 收入： | ||||||||||||
| 協作收入 | $ | - | $ | - | $ | 16,000,000 | $ | - | ||||
| 補助金收入 | - | - | 2萬個 | - | ||||||||
| 總收入 | - | - | 16,020,000 | - | ||||||||
| 運營費用： | ||||||||||||
| 一般和行政 | 1,380,997 | 1,415,844 | 4,215,411 | 3,782,596 | ||||||||
| 研究和開發 | 1,317,231 | 1,085,010 | 3,717,570 | 2,915,392 | ||||||||
| 過程中的研發減值 | 2,008,000 | 1,904,314 | 2,008,000 | 1,904,314 | ||||||||
| 或有對價公允價值的變化 | (1,103,991) | 1,513,400 | (995,951) | 1,865,945 | ||||||||
| 總運營費用 | 3,602,237 | 5,918,568 | 8,945,030 | 10,468,247 | ||||||||
| 營業收入（虧損） | (3,602,237) | (5,918,568) | 7,074,970 | (10,468,247) | ||||||||
| 其他收入（支出），淨額： | ||||||||||||
| 淨利息收入 | 248,840 | 49,912 | 813,989 | 128,464 | ||||||||
| 其他收入（支出），淨額 | (59,929) | 105,715 | (70,724) | 94,493 | ||||||||
| 其他收入總額，淨額 | 188,911 | 155,627 | 743,265 | 222,957 | ||||||||
| 淨收益（虧損） | $ | (3,413,326) | $ | (5,762,941) | $ | 7,818,235 | $ | (10,245,290) | ||||
| 認股權證重置條款中的視作股息 | - | (530,985) | - | (530,985) | ||||||||
| 歸屬於普通股股東的淨虧損 | $ | (3,413,326) | $ | (6,293,926) | $ | 7,818,235 | $ | (10,776,275) | ||||
| 普通股每股淨收益（虧損）——基本 | $ | (0.81) | $ | (7.30) | $ | 2.08 | $ | (23.35) | ||||
| 加權平均流通股數-基本 | 4,214,950 | 789,656 | 3,757,467 | 438,687 | ||||||||
| 普通股每股淨收益（虧損）——攤薄 | $ | (0.81) | $ | (7.30) | $ | 1.91 | $ | (23.35) | ||||
| 加權平均流通股數-攤薄 | 4,214,950 | 789,656 | 4,092,880 | 438,687 | ||||||||
| 其他綜合收益（虧損）： | ||||||||||||
| 淨收益（虧損） | $ | (3,413,326) | $ | (5,762,941) | $ | 7,818,235 | $ | (10,245,290) | ||||
| 有價證券的未實現收益 | 76,435 | - | 73,607 | - | ||||||||
| 外幣折算調整 | 94,094 | (40,310) | 33,988 | (83,430) | ||||||||
| 綜合收益（虧損） | $ | (3,242,797) | $ | (5,803,251) | $ | 7,925,830 | $ | (10,328,720) | ||||
